Alife Health (Alife), the leading technology company building AI tools to advance in-vitro fertilization (IVF) in the US today, announced a new partnership with US Fertility, the nation’s largest partnership of physician-owned fertility practices. US Fertility clinics will pilot Alife’s Embryo Assist™ software to enrich embryo cataloging and to give IVF patients advanced insight into their state-of-the-art embryology laboratories.

Alife’s Embryo Assist™ integrates seamlessly with laboratory microscopes, enabling embryologists to easily capture embryo images and data to elevate laboratory quality-control measures. The tool generates comprehensive activity and audit trails for each embryo, while its cloud-based platform provides real-time lab updates, ensuring embryologists have immediate access to the latest data for informed decision-making.

“Our partnership with Alife marks a significant advancement in our laboratory capabilities,” said Kate Devine, MD, Medical Director and Chief Research Officer of US Fertility. “By integrating AI and data-driven tools into our IVF processes, we aim to continue delivering exceptional care to our patients while providing them with further insight into the precision and consistency of our laboratories.”

With more than 200 physicians in fertility centers nationwide, US Fertility performs over 50,000 IVF retrieval cycles annually and has helped more than 225,000 individuals and couples on their journey to build their families through assisted reproductive technology. The pilot of Embryo Assist™ is expected to further enhance US Fertility’s data capabilities and patient integration.

“Alife is honored to partner with US Fertility to bring our cutting-edge AI solutions into their laboratories,” said Melissa Teran, CEO of Alife Health. “Through this pilot collaboration, we will equip embryologists with a powerful tool that streamlines operations and enhances clinical efficiency. Together, we are advancing IVF through innovation.”